Goldman Sachs Bullish On Avidity Biosciences, Cites Scalable RNA Therapeutics Platform For Rare Diseases

Goldman Sachs has initiated coverage on Avidity Biosciences Inc RNA based on multi-blockbuster, first-tomarket commercial opportunities for its investigational candidates. Avidity Biosciences is a clinical-stage biotechnology company that develops RNA therapeutics (antibody oligonucleotide conjugates) for muscular dystrophies. The company's lead asset, del-desiran (AOC 1001), is currently in the Phase 3 HARBOR trial in patients with myotonic dystrophy type 1 (DM1). The company's pipeline includes Del-brax i ...